Ads
related to: latest developments in schizophrenia treatmentdoconsumer.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
Cobenfy offers new hope for people with schizophrenia, providing an innovative treatment option that could change how this condition is managed, according to Jelena Kunovac, MD, a board-certified ...
The medicine works in an entirely different way from existing treatments.
Minerva believed that the findings of this second trial supported the claim that the drug was an effective agent for the treatment of negative symptoms in schizophrenia. However, in October 2022, FDA sent Minerva a refusal to file letter pertaining to the New Drug Application for roluperidone for treating negative symptoms in schizophrenia ...
Brilaroxazine (developmental code name RP5063), also known as oxaripiprazole, [1] [2] is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of neuropsychiatric and inflammatory disorders. [3] [5] [6] [7] It has currently completed the first of two phase III clinical trials for ...
The Brief Negative Symptom Scale (BNSS) has been used to assess the effect of Ulotaront on the negative symptoms of schizophrenia. [18] In July 2023, the pharmaceutical company behind the drug announced that the drug had failed to outperform placebo in the treatment of acutely psychotic patients with schizophrenia, as measured by the PANSS. [19]
Ads
related to: latest developments in schizophrenia treatmentdoconsumer.com has been visited by 10K+ users in the past month